CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262010070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Beata Kaleta. Beteiligte Einrichtung: Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Autoimmune Diseases, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autoimmune kidney diseases (AIKDs) are a consequence of the dysregulation of immune response and the loss of tolerance to self-antigens, which led to glomerulonephritis and tissue damage. Autoantibody-producing B cells, as well as T cells, neutrophils and macrophages play a pivotal role in the pathogenesis and progression of various AIKDs. In recent years, B cell-depleting/modulating therapies and molecules that modulate T cell differentiation pathways and cytokine production have become a new hope for patients with immune-mediated kidney diseases. However, these biologicals often do not bring satisfactory therapeutic benefits, which is most likely related to incomplete B cell depletion of tissue-resident B cells. A new hope is immunotherapy with chimeric antigen receptor (CAR) effector cells. In CAR therapy, immune cells (mostly T cells) are genetically modified to express a CAR, which enables the recognition of the specific antigen on a target cell. This interaction leads to the formation of immune synapse and cytotoxicity. CAR-based strategies are a potent form of cell therapy that offers a better chance for deep and durable response than other recently approved immune therapies. Moreover, CAR-T cells can be programmed for higher precision and safety. This review explores the current landscape of CAR-T cell therapy in AIKDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland.
ORCID-Profile: Beata Kaleta
Zitieren
APA
Kaleta, B. (2025). CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010070
Vancouver
Kaleta B. CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010070
BibTeX
@article{Kaleta2025,
author = {Kaleta, Beata},
title = {CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262010070}
}
EUVIMED